Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human Clinical Evaluation of the Novel Intravenous Contrast Agent SN132D in Patients With Breast and Pancreatic Cancer

NCT04080024 is registered in ClinicalTrials.gov with Spago Nanomedical AB as lead sponsor.

NCT NCT04080024
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04080024 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human Clinical Evaluation of the Novel Intravenous Contrast Agent SN132D in Patients With Breast and Pancreatic Cancer
Lead sponsor
Spago Nanomedical AB
Phase
Phase 1
Overall status
Completed
Start date
August 23, 2019
Completion date
November 30, 2022
Enrollment
14 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, pancreas cancer